REMIFENTANIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Remifentanil, and when can generic versions of Remifentanil launch?
Remifentanil is a drug marketed by Fresenius Kabi Usa, Hikma, and Nivagen Pharms Inc. and is included in three NDAs.
The generic ingredient in REMIFENTANIL is remifentanil hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Remifentanil
A generic version of REMIFENTANIL was approved as remifentanil hydrochloride by FRESENIUS KABI USA on January 16th, 2018.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REMIFENTANIL?
- What are the global sales for REMIFENTANIL?
- What is Average Wholesale Price for REMIFENTANIL?
Summary for REMIFENTANIL
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Drug Prices: | Drug price information for REMIFENTANIL |
| DailyMed Link: | REMIFENTANIL at DailyMed |
US Patents and Regulatory Information for REMIFENTANIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | REMIFENTANIL HYDROCHLORIDE | remifentanil hydrochloride | INJECTABLE;INJECTION | 206223-001 | Jan 16, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Nivagen Pharms Inc | REMIFENTANIL HYDROCHLORIDE | remifentanil hydrochloride | INJECTABLE;INJECTION | 215635-001 | Jun 28, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | REMIFENTANIL HYDROCHLORIDE | remifentanil hydrochloride | INJECTABLE;INJECTION | 210594-001 | Oct 13, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
